Categories: CancerNews

Profound Medical to Release Second Quarter 2024 Financial Results on August 8 – Conference Call to Follow

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

TORONTO, July 18, 2024 (GLOBE NEWSWIRE) — Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its second quarter 2024 financial results after market close on Thursday, August 8, 2024.

Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period.

Second Quarter 2024 Results Conference Call Details:

Date:   Thursday, August 8, 2024
     
Time:   4:30 p.m. ET
     
Live Call Registration:   https://register.vevent.com/register/BIbfa8c9bee6c6463c8ca3a1937fbfd804
     

The call will also be broadcast live and archived on the Company’s website at www.profoundmedical.com under “Webcasts” in the Investors section.

About Profound Medical Corp.

Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.

Profound is commercializing TULSA-PRO®, a technology that combines real-time MRI, robotically-driven transurethral ultrasound and closed-loop temperature feedback control. TULSA-PRO® is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while actively protecting the urethra and rectum to help preserve the patient’s natural functional abilities. TULSA-PRO® has the potential to be a flexible technology in customizable prostate ablation, including intermediate stage cancer, localized radio-recurrent cancer, retention and hematuria palliation in locally advanced prostate cancer, and the transition zone in large volume benign prostatic hyperplasia (“BPH”). TULSA-PRO® is CE marked, Health Canada approved, and 510(k) cleared by the U.S. Food and Drug Administration (“FDA”).

Profound is also commercializing Sonalleve®, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases. Sonalleve® has also been approved by the China National Medical Products Administration for the non-invasive treatment of uterine fibroids and has FDA approval under a Humanitarian Device Exemption for the treatment of osteoid osteoma. The Company is in the early stages of exploring additional potential treatment markets for Sonalleve® where the technology has been shown to have clinical application, such as non-invasive ablation of abdominal cancers and hyperthermia for cancer therapy.

For further information, please contact:

Stephen Kilmer
Investor Relations
skilmer@profoundmedical.com
T: 647.872.4849

Staff

Recent Posts

HemoSonics Wins Best Medical Device Company in Triangle Business Journal’s 2025 Life Sciences Awards

HemoSonics’ Quantra Hemostasis System provides comprehensive blood analysis detailing hemostasis in the operating room in…

51 minutes ago

Alzheimer’s Association Launches Free Mobile App to Support Newly Diagnosed Individuals and Care Partners

– New app developed with input from people living with early-stage dementia, connects families affected…

54 minutes ago

Global Surge in Analytical and Life Science Tools to Push Market Beyond $100 Billion by 2029, New SDi Report Predicts

ARLINGTON, Va., May 27, 2025 /PRNewswire/ -- Strategic Directions International (SDi), part of Science and…

54 minutes ago

Chromatography Accessories & Consumables Market worth US$8.74 billion by 2030 with 7.5% CAGR | MarketsandMarkets™

DELRAY BEACH, Fla., May 27, 2025 /PRNewswire/ -- The global Chromatography Accessories & Consumables Market, valued…

54 minutes ago

Life365 Appoints Healthcare Veteran Jay Roberts as Chief Development Officer

Industry Leader with 30+ Years of Experience Will Drive Strategic Growth and Partnerships SCOTTSDALE, Ariz.,…

54 minutes ago

New Strategic Partnership Between ConnectureDRX and EvolveNXT Unifies Agent Onboarding, Enrollment, and Commissions

MILWAUKEE, Wis. and LOS ANGELES, May 27, 2025 /PRNewswire/ -- ConnectureDRX, the leading provider of…

54 minutes ago